Included in the formulation
АТХ:C.01.E.B Other drugs for the treatment of heart disease
C.01.E.B.06 Phosphocreatine
Pharmacodynamics:It improves myocardial metabolism, intracellular energy transport, inhibits the destruction of sarcolemma of ischemic cardiomyocytes. Stimulates microcirculation, reduces the size and prevents the expansion of the necrosis and ischemia. Under conditions of ischemia and postischemic reperfusion, it exhibits an antiarrhythmic effect: it suppresses the ectopic activity of the ventricles without disturbing the conductivity along the Purkinje fibers.
Pharmacokinetics:With intravenous infusion, the maximum concentration is created in the 2-3rd minute. Passes histogematicallyand it accumulates in the myocardium, the brain, and the skeletal musculature. Elimination is two-phase: the half-life of the fast phase is 20-30 minutes, the slow one is several hours. Excreted in urine.
Indications:Acute myocardial infarction, chronic heart failure, intraoperativeI ischemia of the myocardium, acute violation of cerebral circulation, prevention of the development of the syndrome of physical overstrain, improving adaptation to extreme physical stress.
IX.I20-I25.I20 Angina pectoris [angina pectoris]
IX.I20-I25.I21 Acute myocardial infarction
IX.I20-I25.I25 Chronic ischemic heart disease
IX.I30-I52.I42 Cardiomyopathy
IX.I30-I52.I50.0 Congestive heart failure
IX.I30-I52.I50.9 Heart failure, unspecified
IX.I60-I69.I63 Cerebral infarction
IX.I60-I69.I64 Stroke not specified as a hemorrhage or infarction
XVIII.R00-R09.R07.2 Pain in the region of the heart
Contraindications:Hypersensitivitytion.
Pregnancy and lactation:Category of recommendations FDA is not defined. Qualitative and well-controlled studies on humans and animals have not been conducted.
There is no information on the penetration into breast milk.
Dosing and Administration:Intramuscularly - 0.5-1 g per day; intravenously - 1-2 g per day. In acute myocardial ischemia: on the 1st day - intravenously bolus 2 g followed by a dropwise infusion of 4 g / h for 2 h; 2-6 days - 4-8 g daily. In cardiosurgery add (10 mmol / l) to the cardioplegicallye solutions.
Side effects:Acute hypotension (with rapid intravenous administration at doses exceeding 4 g).
Overdose:Not described.
Treatment is symptomatic.
Interaction:Increases the effectiveness of antiarrhythmic, antianginal and cardiotonic drugs.
Special instructions:Phosphocreatine is not a first-line drug for the treatment of these diseases and its use is not necessary. There is no information on the effect on clinically relevant outcomes.